Group 1 (N = 1630) was T2DM with both study drugs, group 2 (N = 3359) was T2DM with SGLT-2 inhibitors, group 3 (N = 10,547) was T2DM with Pio, and group 4, the reference group (N = 81,488), was T2DM with non-study drugs (Figure 1). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.